88 citations,
September 2003 in “Clinical endocrinology” Hormone treatment for transsexual individuals is effective but carries risks like thromboembolic events and mood changes, with most side effects being minor and reversible.
57 citations,
January 2004 in “Journal of Endocrinology” Baldness caused by male hormones in female-to-male transsexuals doesn't increase the risk of heart disease.
105 citations,
June 2010 in “The journal of sexual medicine” Testosterone undecanoate increases lean mass and causes various physical changes in female-to-male transsexuals.
July 1996 in “International Journal of Dermatology” The book "Hair Replacement" is a detailed guide on all methods of hair replacement, recommended for those interested in the field.
157 citations,
May 2016 in “Plastic and reconstructive surgery/PSEF CD journals” Facial feminization surgery is safe and patients are satisfied, but more detailed research is needed.
176 citations,
August 2000 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Hormone treatments in transsexual individuals reduce hair growth and oil production in male-to-females and increase them in female-to-males.
28 citations,
November 2003 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” The normal human prostate does not significantly affect blood DHT levels.
January 2016 in “Dermatology Online Journal” Hormonal therapy changes skin and hair in transgender patients, who need better researched dermatologic care.
110 citations,
January 2014 in “The Journal of Sexual Medicine” Testosterone treatment in trans men increases body and facial hair and may lead to hair loss over time, but severe skin issues are rare.
21 citations,
November 2014 in “Journal of Endocrinological Investigation” Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.
13 citations,
March 2016 in “Progress in Transplantation” Healthcare providers need better understanding and cultural sensitivity to improve care for transgender patients with kidney failure needing transplants.
34 citations,
November 2017 in “Gynecological Endocrinology” A transwoman developed a brain tumor after nine years of hormone therapy, suggesting a possible link between the treatment and tumor development.
32 citations,
January 2018 in “American Journal of Clinical Dermatology” Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.
January 2012 in “S. Karger AG eBooks” The document concludes that transsexual individuals often experience improved quality of life after transitioning, despite higher risks of psychiatric issues and mortality.
4809 citations,
January 2004 in “Fertility and Sterility” The 2003 consensus updated PCOS diagnosis criteria and highlighted increased risks of diabetes and heart disease for those affected.
4025 citations,
December 2003 in “Human Reproduction” The 2003 consensus updated PCOS diagnosis criteria and linked PCOS to higher risks of diabetes and heart problems, recommending lifestyle changes to lower these risks.
2295 citations,
August 2012 in “The international journal of transgenderism/International journal of transgenderism” The guidelines recommend informed consent for gender-affirming treatments and stress the importance of personalized, culturally sensitive care for transgender individuals.
989 citations,
August 2007 in “The Lancet” PCOS is a complex condition with major health impacts, needing more research for better diagnosis and treatment.
855 citations,
June 2009 in “The Journal of Clinical Endocrinology & Metabolism” The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.
658 citations,
June 2003 in “Endocrine reviews” Male hormones may play a role in the development of heart disease, and more research is needed to understand their effects.
475 citations,
January 2016 in “International Review of Psychiatry” The document concludes that non-binary individuals need compassionate support and recognition in healthcare, without being pathologized.
418 citations,
June 2003 in “Endocrine Reviews” While PCOS might increase the risk of heart disease, there's not strong evidence to prove it causes earlier heart problems.
393 citations,
November 2000 in “Archives of General Psychiatry” Testosterone is important for men's sexual function, may help some women's sexual desire, while other hormones and neurotransmitters also play complex roles in sexual behavior.
253 citations,
March 2006 in “The Journal of Clinical Endocrinology and Metabolism” Exposure to too much androgen before birth might cause polycystic ovary syndrome later in life.
249 citations,
November 2003 in “Clinical endocrinology” Insulin resistance is a key factor in polycystic ovary syndrome, but genetics may also contribute.
204 citations,
May 2014 in “The Journal of Sexual Medicine” Hormone therapy for trans individuals is effective and generally safe in the short term.
166 citations,
October 2018 in “Endocrine Reviews” Hormone treatments for transgender individuals generally improve mental health and physical transition, with some health risks that require medical supervision.
166 citations,
March 2007 in “Hypertension” High androgen levels in young women with PCOS are linked to higher blood pressure.
162 citations,
April 2016 in “The Lancet Diabetes & Endocrinology” Testosterone therapy in transgender men has both desired effects like increased muscle mass and potential health risks such as higher cardiovascular risk.
146 citations,
December 2016 in “Translational Andrology and Urology” Hormone therapy is essential for transgender individuals but requires careful management due to possible metabolic effects.